Journey Medical (DERM) Net Income towards Common Stockholders (2020 - 2026)

Journey Medical's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 45.25% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.6 million (down 16.11% YoY) and the FY2025 annual result came in at -$11.4 million, up 22.21% from the prior year.
• Net Income towards Common Stockholders was -$2.2 million for Q1 2026 at Journey Medical, down from -$1.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $16.8 million in Q3 2023 and bottomed at -$10.6 million in Q4 2022.
• A 5-year average of -$3.6 million and a median of -$3.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 266.56% in 2023, while the deepest fall reached 635.56% in 2023.
• Journey Medical's Net Income towards Common Stockholders stood at -$10.6 million in 2022, then soared by 79.86% to -$2.1 million in 2023, then soared by 173.82% to $1.6 million in 2024, then plunged by 177.69% to -$1.2 million in 2025, then plunged by 81.45% to -$2.2 million in 2026.
• Business Quant data shows DERM's Net Income towards Common Stockholders at -$2.2 million in Q1 2026, -$1.2 million in Q4 2025, and -$2.3 million in Q3 2025.